Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 17-Apr-19 9:35 AM View:  | Danilkovitch Alla Chief Scientific Officer | Osiris Therapeutics, Inc. (OSIR) | 17-Apr-19 | Disposition | 9,375 | $19.00 | $178,125.00 | (100%) 9.38K to 0 | < 1% |
| 17-Apr-19 9:36 AM View: | Friedli Peter Director | Osiris Therapeutics, Inc. (OSIR) | 17-Apr-19 | Disposition | 10,204,400 | $19.00 | $193,884,000.00 | (69%) 14.81M to 4.61M | < 1% |
| 17-Apr-19 9:36 AM View: | Friedli Peter Director | Osiris Therapeutics, Inc. (OSIR) | 17-Apr-19 | Disposition | 4,606,050 | $19.00 | $87,515,000.00 | (100%) 4.61M to 0 | < 1% |
| 17-Apr-19 9:35 AM View: | Keefer Jason Chief Commercial Officer | Osiris Therapeutics, Inc. (OSIR) | 17-Apr-19 | Disposition | 4,000 | $19.00 | $76,000.00 | (100%) 4.0K to 0 | < 1% |
| 25-Jul-18 4:20 PM View: | Venturetec Inc | Osiris Therapeutics, Inc. (OSIR) | 24-Jul-18 | Disposition (other) | 3,000,000 | -- | -- | (100%) 3.0M to 0 | |
| 09-Jul-18 4:21 PM View: | Venturetec Inc 10% Owner | Osiris Therapeutics, Inc. (OSIR) | 05-Jul-18 | Disposition (other) | 1,103,300 | -- | -- | (27%) 4.1M to 3.0M | |
| 26-Jan-17 4:21 PM View: | Dresner David A Interim President & CEO | Osiris Therapeutics, Inc. (OSIR) | 25-Jan-17 | Option Exercise | 15,000 | $5.30 | $79,500.00 | 150% 10.0K to 25.0K | 260% |
| 24-Jan-17 4:07 PM View: | Dresner David A Interim President & CEO | Osiris Therapeutics, Inc. (OSIR) | 23-Jan-17 | Option Exercise | 5,000 | $5.03 | $25,150.00 | 100% 5.0K to 10.0K | 279% |
| 17-Jan-17 8:55 PM View: | Dresner David A Interim President & CEO | Osiris Therapeutics, Inc. (OSIR) | 12-Jan-17 | Option Exercise | 5,000 | $4.75 | $23,750.00 | 100% 0 to 5.0K | 302% |
| 20-Nov-15 5:48 PM View: | Debrabandere Lode President & CEO | Osiris Therapeutics, Inc. (OSIR) | 20-Nov-15 | Option Exercise | 37,500 | $6.84 | $256,500.00 | 100% 0 to 37.5K | |
| 20-Nov-15 5:47 PM View: | Danilkovitch Alla Chief Scientific Officer | Osiris Therapeutics, Inc. (OSIR) | 19-Nov-15 | Option Exercise | 4,000 | $5.08 | $20,320.00 | 50% 7.95K to 11.95K | |
| 11-Aug-15 6:32 AM View: | Danilkovitch Alla Chief Scientific Officer | Osiris Therapeutics, Inc. (OSIR) | 10-Aug-15 | Market Option Sale | 2,425 | $18.22 | $44,183.50 | (23%) 10.38K to 7.95K | (6%) |
| 11-Aug-15 6:32 AM View: | Danilkovitch Alla Chief Scientific Officer | Osiris Therapeutics, Inc. (OSIR) | 10-Aug-15 | Option Exercise | 5,000 | $0.40 | $2,000.00 | 93% 5.38K to 10.38K | |
| 08-Jun-15 4:01 PM View: | Law Gregory Ivan Principal Accounting Officer | Osiris Therapeutics, Inc. (OSIR) | 04-Jun-15 | Market Purchase | 100 | $18.83 | $1,883.00 | 100% 0 to 100 | 3% |
| 29-May-15 4:30 PM View: | Jacoby Philip R Jr Chief Financial Officer | Osiris Therapeutics, Inc. (OSIR) | 27-May-15 | Option Exercise | 20,000 | $7.35 | $147,034.00 | 160% 12.5K to 32.5K | |
| 29-May-15 4:30 PM View: | Jacoby Philip R Jr Chief Financial Officer | Osiris Therapeutics, Inc. (OSIR) | 27-May-15 | Market Option Sale | 20,000 | $18.55 | $371,080.00 | (62%) 32.5K to 12.5K | (4%) |
| 30-May-14 5:51 PM View: | Neumayer Matthew Paul Principal Accounting Officer | Osiris Therapeutics, Inc. (OSIR) | 29-May-14 | Option Exercise | 500 | $6.46 | $3,230.00 | 100% 0 to 0.5K | |
| 30-May-14 5:51 PM View: | Neumayer Matthew Paul Principal Accounting Officer | Osiris Therapeutics, Inc. (OSIR) | 29-May-14 | Market Option Sale | 500 | $15.55 | $7,775.00 | (100%) 0.5K to 0 | (24%) |
| 29-May-14 8:47 AM View: | Neumayer Matthew Paul Principal Accounting Officer | Osiris Therapeutics, Inc. (OSIR) | 27-May-14 | Option Exercise | 3,750 | $6.95 | $26,078.80 | 64% 5.88K to 9.63K | |
| 29-May-14 8:47 AM View: | Neumayer Matthew Paul Principal Accounting Officer | Osiris Therapeutics, Inc. (OSIR) | 27-May-14 | Market Option Sale | 3,750 | $16.10 | $60,375.00 | (39%) 9.63K to 5.88K | (20%) |
| 23-May-14 6:53 AM View: | Jacoby Philip R Jr Chief Financial Officer | Osiris Therapeutics, Inc. (OSIR) | 21-May-14 | Option Exercise | 15,947 | $7.35 | $117,166.00 | 128% 12.5K to 28.45K | |
| 23-May-14 6:53 AM View: | Jacoby Philip R Jr Chief Financial Officer | Osiris Therapeutics, Inc. (OSIR) | 21-May-14 | Market Option Sale | 15,947 | $15.43 | $245,998.00 | (56%) 28.45K to 12.5K | (25%) |
| 17-Mar-14 4:04 PM View: | Williams Michelle Leroux Chief Scientific Officer | Osiris Therapeutics, Inc. (OSIR) | 14-Mar-14 | Market Option Sale | 11,934 | $13.91 | $166,009.00 | (100%) 11.93K to 0 | (39%) |
| 17-Mar-14 4:04 PM View: | Williams Michelle Leroux Chief Scientific Officer | Osiris Therapeutics, Inc. (OSIR) | 14-Mar-14 | Option Exercise | 11,934 | $12.01 | $143,327.00 | 100% 0 to 11.93K | |
| 17-Mar-14 4:04 PM View: | Williams Michelle Leroux Chief Scientific Officer | Osiris Therapeutics, Inc. (OSIR) | 13-Mar-14 | Market Option Sale | 50,000 | $14.14 | $706,925.00 | (100%) 50.0K to 0 | (37%) |
| 17-Mar-14 4:04 PM View: | Williams Michelle Leroux Chief Scientific Officer | Osiris Therapeutics, Inc. (OSIR) | 13-Mar-14 | Option Exercise | 50,000 | $7.18 | $358,938.00 | 100% 0 to 50.0K | |
| 07-Feb-14 12:31 PM View: | Klingemann Hans-Georg Director | Osiris Therapeutics, Inc. (OSIR) | 06-Feb-14 | Grant | 5,000 | $14.93 | $74,650.00 | 400% 1.25K to 6.25K | 29% |
| 07-Feb-14 9:33 AM View: | Gutzwiller Felix Director | Osiris Therapeutics, Inc. (OSIR) | 06-Feb-14 | Grant | 7,000 | $14.93 | $104,510.00 | 9% 77.5K to 84.5K | 29% |
| 07-Feb-14 9:33 AM View: | Friedli Peter Director 10% Owner | Osiris Therapeutics, Inc. (OSIR) | 06-Feb-14 | Grant | 10,000 | $14.93 | $149,300.00 | < 1% 14.8M to 14.81M | 29% |
| 21-Jan-14 7:49 AM View: | Friedli Peter Director 10% Owner | Osiris Therapeutics, Inc. (OSIR) | 17-Jan-14 | Acquisition (other) | -- | -- | -- | 0% 14.8M | |
| 26-Nov-13 6:53 AM View: | Jacoby Philip R Jr Chief Financial Officer | Osiris Therapeutics, Inc. (OSIR) | 25-Nov-13 | Option Exercise | 18,372 | $6.44 | $118,233.00 | 48% 38.37K to 56.74K | |
| 26-Nov-13 6:53 AM View: | Jacoby Philip R Jr Chief Financial Officer | Osiris Therapeutics, Inc. (OSIR) | 25-Nov-13 | Market Option Sale | 18,372 | $15.99 | $293,680.00 | (32%) 56.74K to 38.37K | (21%) |
| 18-Nov-13 6:49 PM View: | Williams Michelle Leroux Chief Scientific Officer | Osiris Therapeutics, Inc. (OSIR) | 15-Nov-13 | Option Exercise | 24,500 | $3.18 | $77,975.00 | 100% 0 to 24.5K | |
| 18-Nov-13 6:49 PM View: | Williams Michelle Leroux Chief Scientific Officer | Osiris Therapeutics, Inc. (OSIR) | 15-Nov-13 | Market Option Sale | 24,500 | $15.50 | $379,632.00 | (100%) 24.5K to 0 | (25%) |
| 20-Aug-13 12:53 PM View: | Neumayer Matthew Paul Principal Accounting Officer | Osiris Therapeutics, Inc. (OSIR) | 20-Aug-13 | Option Exercise | 11,375 | $10.43 | $118,615.00 | 100% 0 to 11.38K | |
| 20-Aug-13 12:53 PM View: | Neumayer Matthew Paul Principal Accounting Officer | Osiris Therapeutics, Inc. (OSIR) | 20-Aug-13 | Market Option Sale | 11,375 | $19.75 | $224,656.00 | (100%) 11.38K to 0 | 2% |
| 16-Aug-13 8:58 PM View: | Friedli Peter Director 10% Owner | Osiris Therapeutics, Inc. (OSIR) | 14-Aug-13 | Payment of Exercise | 432,390 | $25.44 | $11,000,000.00 | (3%) 15.23M to 14.8M | 24% |
| 16-Aug-13 8:58 PM View: | Friedli Peter Director 10% Owner | Osiris Therapeutics, Inc. (OSIR) | 14-Aug-13 | Option Exercise | 1,000,000 | $11.00 | $11,000,000.00 | 7% 14.23M to 15.23M | |
| 13-Feb-13 5:31 PM View: | Moyes Jay M Director | Osiris Therapeutics, Inc. (OSIR) | 12-Feb-13 | Grant | 5,000 | $7.73 | $38,650.00 | 30% 16.5K to 21.5K | 150% |
| 13-Feb-13 5:31 PM View: | Gutzwiller Felix Director | Osiris Therapeutics, Inc. (OSIR) | 12-Feb-13 | Grant | 7,000 | $7.73 | $54,110.00 | 10% 70.5K to 77.5K | 150% |
| 13-Feb-13 5:30 PM View: | Friedli Peter Director 10% Owner | Osiris Therapeutics, Inc. (OSIR) | 12-Feb-13 | Grant | 10,000 | $7.73 | $77,300.00 | < 1% 14.22M to 14.23M | 150% |
| 13-Feb-13 5:32 PM View: | Klingemann Hans-Georg Director | Osiris Therapeutics, Inc. (OSIR) | 12-Feb-13 | Grant | 1,250 | $7.73 | $9,662.50 | 100% 0 to 1.25K | 150% |
| 07-Feb-14 9:33 AM View: | Moyes Jay M Director | Osiris Therapeutics, Inc. (OSIR) | 06-Feb-13 | Grant | 5,000 | $14.93 | $74,650.00 | 23% 21.5K to 26.5K | |
| 11-Dec-12 5:20 PM View: | Williams Michelle Leroux Chief Scientific Officer | Osiris Therapeutics, Inc. (OSIR) | 11-Dec-12 | Private Purchase | 520 | $0.40 | $208.00 | 100% 0 to 0.52K | |
| 11-Dec-12 5:20 PM View: | Williams Michelle Leroux Chief Scientific Officer | Osiris Therapeutics, Inc. (OSIR) | 11-Dec-12 | Market Sale | 520 | $9.31 | $4,839.64 | (100%) 0.52K to 0 | (108%) |
| 10-Dec-12 7:54 AM View: | Venturetec Inc 10% Owner | Osiris Therapeutics, Inc. (OSIR) | 10-Dec-12 | Market Sale | 50,000 | $9.52 | $476,000.00 | (1%) 4.15M to 4.1M | (103%) |
| 10-Dec-12 7:54 AM View: | Friedli Peter Director 10% Owner | Osiris Therapeutics, Inc. (OSIR) | 10-Dec-12 | Market Sale Duplicate | 50,000 | $9.52 | $476,000.00 | (< 1%) 14.27M to 14.22M | (103%) |
| 16-Nov-12 6:54 AM View: | Friedli Peter Director 10% Owner | Osiris Therapeutics, Inc. (OSIR) | 15-Nov-12 | Private Sale | 625 | $9.34 | $5,837.50 | (< 1%) 14.27M to 14.27M | |
| 27-Mar-12 2:25 PM View: | Gutzwiller Felix Director | Osiris Therapeutics, Inc. (OSIR) | 23-Mar-12 | Grant | 7,000 | $5.08 | $35,560.00 | 11% 63.5K to 70.5K | 280% |
| 27-Mar-12 2:25 PM View: | Friedli Peter Director 10% Owner | Osiris Therapeutics, Inc. (OSIR) | 23-Mar-12 | Grant | 10,000 | $5.08 | $50,800.00 | < 1% 14.26M to 14.27M | 280% |
